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have failed PBSC mobilization is high. Auto-BMT should not be
routinely recommended to pts who have failed PBSC mobilization.
Alternative strategies, including reduced intensity or non-myeloa-




AN AUDITED RETROSPECTIVE ANALYSIS OF CORD BLOOD TRANS-
PLANTATION (CBT) OF 230 PATIENTS USING PLASMA DEPLETED
CORD BLOOD UNITS (PD CB)
Chow, R.1,2,3, Wang, B.1, Wu, T.1, Chow, T.1, Gjertson, D.4, Petz, L.1
1StemCyte International Cord Blood Center, Arcadia, CA; 2StemCyte
Taiwan National Cord Blood Center, Linkou, Taiwan; 3StemCyte Re-
search Institute, Arcadia, CA; 4UCLA School of Public Health & UCLA
School of Medicine, Los Angeles, CA.
Limited cell dose has hampered widespread use of CBT. The red
cell depletion (RD) techniques that are widely used incur signiﬁ-
cant nucleated cell loss after processing; therefore, to minimize cell
loss and still reduce volume during processing, a technique was
devised to deplete plasma (PD) but not red blood cells. An updated
retrospective audited analysis of 230 consecutive patients with
engraftment and/or survival data from 81 transplant centers over 5
continents up to September 2006 was performed. The data was
audited in three ways: (1) by CIBMTR using on-site audits for
40% of the PD CBT with available outcome data, (2) by NMDP
for PD CBT that it faciliates, (3) and by the transplant center
working with the cord blood bank. Patient characteristics: median
age 7.9 yo, range 0.3-63, 66 16 yo (29%); median weight 27 kg,
range 4.8-137, 70,50kg (31%); male 59%; median # HLA ABDR
matches 4.0; median pre-freeze TNC dose 5.6  107/kg (n230);
transplant center reported median post-thaw TNC dose 3.9 
107/kg (n219); median pre-freeze CD34 dose 1.8  105/kg;
malignant indications 69%; transplants outside U.S. 37%; double
cord transplant 25%; and non-myeloablative 19%. Of the malig-
nant cases, 40 (26%) had standard risks, 91 (59%) had advanced
risks, and 24 (15%) with unknown status. For all engrafted pa-
tients, the median time to engraftment for ANC 500, platelet 20K
and 50K were 22 days (range 6-69), 48 days (range 12-186), and 62
days (range 21-374) respectively. Kaplan-Meier estimates of en-
graftment of ANC500, platelet 20K and 50K engraftment were
892% (n215), 784% (n196) and 754% (n195) respec-
tively. The incidence of grade III-IV acute GVHD and extensive
chronic GVHD were 13% and 12% respectively. One-year relapse
rate was 254% for all patients (n223), and TRM was 193%
and 293% (n228) at 100 days and 1 year. With a median
follow-up of 258 days (range 2-1741 days) for the surviving pa-
tients, the Kaplan-Meier estimates of 1-year OS (n228) and DFS
(n223) are 583% and 563% respectively. To our knowledge,
this is one of few studies originated by cord blood banks that was
extensively audited by external data and transplant registries. Other
unique aspects were the very high mean and median cell dose as
well as the minority and international focus of the patients. These
results conﬁrm our earlier ﬁndings and demonstrate that CBT
using PD CB can achieve outstanding engraftment and survival.
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A PILOT STUDY CD34 SELECTED HAPLOIDENTICAL TRANSPLANT US-
ING A CHEMOTHERAPY ONLY PREPARATIVE REGIMEN AND INTENSIVE
ANTIBIOTIC PROPHYLAXIS FOR TREATMENT OF ADVANCED LEUKEMIA
Gajewski, J.L.1, McMannis, J.D.2, Shpall, E.J.2, Donato, M.L.3,
Champlin, R.E.2 1Temple University/Fox Chase-Temple BMT Pro-
gram, Philadelphia, PA; 2University of Texas/M.D. Anderson Cancer
Center, Houston, TX; 3Hackensack University, Hackensack, NJ.
We present preliminary data of haploidentical transplant for 13
patients (pts) with acute leukemia using a chemotherapy-only pre-
parative regimen of Melphalan 140 mg/m2 on day –8; Thiotepa 10
mg/kg on day –7; Fludarabine 40 mg/m2 on days –6, -5, -4, -3; 1.5
mg/kg of rabbit ATG/day days –6, -5, -4, -3.aˆ device as a means of
T-cell depletion. All products had 1  104 CD3 T-cells/kg
recipient body weight and needed a minimum of 5  106 CD34
cells/kg but preferably 1  107 CD34 cells/kg recipient body
weight. Age ranged 23-50 years/median 37 years, four patients
were in advanced remission and nine were in refractory relapse.
Patients received intensive PCP prophylaxis with sulfamethox-
azole-trimethoprim and pentamidine prior to transplant and dur-
ing pancytopenia; CMV prophylaxis with valganciclovir during the
BMT prep and foscarnet® while pancytopenic; and with liposomal
amphotericin or cancidas for fungal prophylaxis.
Two patients had primary graft failure-one survived disease free
and one relapsed. One patient died of multiple organ failure prior
to engraftment. Median time to engraftment was 15 days (range,
9-26) to 500 neutrophils and 14 days to platelets 20,000 (range,
13-25).
Seven patients died of relapse at a median of 10 months (range
2-13 months), and one patient died of a viral infection. Two of 10
patients who engrafted developed grade one acute graft-versus-
host (GVHD) and four patients had chronic GVHD (3 limited, 1
extensive). Four patients survive beyond 2 years, without recurrent
disease.
This report for haploidentical transplant demonstrates that a
chemotherapy only preparative regimen can achieve a high rate of
engraftment. Infectious complications were minimal with aggres-
sive prophylaxis. Long-term remission are achievable with little
risk of severe GVHD with t-cell depletion with use of CliniMACSaˆ
in haploidentical stem cell transplant.
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COMBINED BONE MARROW AND PBPC AUTOGRAFTS FOR TRANSPLAN-
TATION OF PATIENTS WITH POOR MOBILIZATION
Sinitsyn, Y.1, Grosskreutz, C.1, Osman, K.1, Scigliano, E.1, Isola, L.1
1Mount Sinai Medical Center, New York, NY.
Background: Autologous BMT has been abandoned in favor of
PBSC collected after G-CSF with or without chemotherapy.
PBPC autografts with low CD34 cell content provide late neu-
trophil and inadequate platelet and red cell reconstitution. Repeat
mobilization and bone marrow harvest are possible ways to cir-
cumvent this problem. No studies address minimum cell contents
for combined PBPC/BM grafts and transplant outcomes using
combined grafts in the context of previous inadequate PBSC col-
lection. Methods: Retrospective analysis of 19 autologous trans-
plants performed with a combined PBPC/BM graft for poor initial
PBPC collection. Mobilization was ﬁlgrastim 10 g/kg/day with-
out chemotherapy x 5 days or after CY, ICE or RICE to peripheral
CD34 count  10/L and until completion of collection. A
standard BM harvest (max 20 mL/kg) was done if collection con-
tained  2.5  106 CD34 / kg. Results: Patients median age was
55 (19-74). Diagnoses: MM (7), NHL (7), HL (4) and AML (1).
Cell contents of the combined grafts were (CD34 / kg x 106
median  standard deviation (range)) for BM 1.1 0.6 (0.3-2.7)
PBPC 1.2  0.7 (0.04-2.8) Infused: 2.2  1.1 (1.4-4.7). Eight
combined grafts contained  2.0  106 CD34 / kg (1.3-1.8).
Engraftment in days as median (range) was: ANC500: 11 (9-39) Plt
20,000: 25 (15-59) RBC independence: 28 (0-58). Six patients died
of progressive disease (58-293 days post-ASCT). One patient died
of infection day 141 and one of MI day 11. All patients maintained
an ANC 1,000 without growth factor support beyond day 19 but
one who required intermittent growth factor support until day 39.
One patient experienced delayed graft failure (platelets  10,000)
on day 90 at concomitantly with acute cholecystitis. The CD34 /
kg content of the PBPC collection alone did not predict that of the
BM harvest but it correlated with time to ANC500 (r  -0.46 p 
0.046) and time to Plt 20,000 (r  -0.54 p  0.037). Neither the
BM nor the total infused CD34 / kg content or the BM TNC/kg
content correlated with engraftment or outcomes. In particular,
patients above or below 2.0  106 CD34/kg had similar kinetics
of engraftment and overall mortality. Conclusions: BM harvest
after failed PBPC collection is a reliable option to obtain an
adequate combined autograft. Combined BM/PBSC grafts can
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produce adequate engraftment even when the CD34/kg content
is below what is considered a minimum target for PBSC alone.
Registry data may already exist to address this issue.
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EVIDENCE OF SUCCESSFUL ALLOGENEIC TRANSPLANTAITON USING
CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS FROM HEALTHY
DONORS
Kim, D.H.12, Jamal, N.1, Saragosa, R.1, Lipton, J.H.1, Gupta, V.1,
Kuruvilla, J.1, Messner, H.A.1 1Princess Margaret Hospital, Toronto,
ON, Canada; 2Samsung Medical Center, Seoul, Republic of Korea.
Between Sep 2003 and Dec 2005, the BMT program at Princess
Margaret Hospiral (Toronto, ON, Canada) performed 105 trans-
plants using cryopreserved PBSCs from allogeneic related donors.
The current study was aimed to evaluate the safety of cryopreser-
vation of PBSCs, to compare the clinical outcomes of cryopre-
served PBSCT with fresh PBSCT, and to evaluate the inﬂuence of
cryopreservation on colony forming unit (CFU) assay data of
PBSCs incluidng CFU-GM, BFU-E, CFU-MEG and CFU-
GEMM. As a control group, 106 patients receiving fresh PBSCTs
between Jun 2001 and Aug 2003 was compared.
All patients tolerated well to infusion without signiﬁcant toxicity.
The mean viability of thawed products was 71.21.0%. The me-
dian transplant dose of TNC and CD34 cells was 8.9108/Kg
and 5.0106/Kg, while that of CFU-GM, BFU-E, CFU-MEG
and CFU-GEMM was 118, 134, 19, 8.4104/Kg, respectively. No
differences in clinical outcomes were noted between cryo- vs.
fresh-PBSCT group: engraftment of neutrophil (p0.178) or
platelet (p0.785), acute GVHD (p0.113), chronic GVHD
(p0.673), recurrence (p0.295), non-relapse mortality
(p0.340), and overall survival (p0.668). The colony forming
activity was reduced by 24.62.5% for CFU-GM, 30.52.5% for
BFU-E, 61.43.1% for CFU-MEG, and 21.32.1% for CFU-
GEMM after cryopreservation. The transplant CD34 cell dose
correlates well with transplant dose of CFU-GM (p0.001),
BFU-E (p0.001), CFU-MEG (p0.001) and CFU-GEMM
(p0.049), but not with TNC dose. The group receiving higher
transplant CD34 cell dose showed signiﬁcantly faster engraft-
ment of neutrophil (0.5109/L, p0.012) and platelet
(20109/L, p0.013 and 100109/L, p0.009). Moreover,
transplant CFU-MEG dose showed good correlation with engraft-
ment of platelet above 20109/L (p0.029), 50109/L (p0.003),
and 100109/L (p0.001). In multivariate analysis, higher CFU-
MEG dose was strongly correlated with faster engraftment above
100109/L when taking into account as a continuous (p0.001) or
categorical variables (p0.040).
Conclusion
1) Cryopreserved PBSCT is safe in terms of infusion-related
toxocitiy, and showed equivalent transplant outcomes to fresh
PBSCT.
2) CFU-MEG decreases by 60% after cryopreservation, but
other CFUs showed similar decrease as viability.
3) Transplant CD34 cell dose correlated well with engraftment
of neutrophil and platelet. However, in terms of stable platelet
engraftment (100109/L), CFU-MEG dose seemed to be more
important factor than CD34 cell dose.
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DEVELOPMENT OF A MINIMALLY INVASIVE DEVICE AND METHOD FOR
RAPID, OUTPATIENT HARVEST OF BONE MARROW
Kraft, D.1, Milroy, C.1, MacKenzie, A.2, Ghazarossian, V.2 1Stanford
University School of Medicine, Stanford, CA; 2StemCor Systems Inc,
Menlo Park, CA.
Bone marrow is a rich source of adult stem cells. Traditional
methods for harvesting marrow derived stem cells are crude, te-
dious and expensive. We have developed a device and method for
the minimally invasive harvest of bone marrow which may enable
the rapid, convenient outpatient harvest of large quantities of
marrow derived cells under local anesthesia.
Marrow contains a rich supply of hematopoetic, mesenchymal
and other adult stem cell populations. Both marrow and mobilized
peripheral blood stem cells are currently utilized in BMT. For
allogeneic transplants, recent data suggests operatively harvested
marrow (as well as GCSF-primed marrow) may lead to less chronic
GVHD and better overall outcomes than mobilized PBSC grafts.
In addition to BMT, marrow derived cells may soon be utilized in
a variety of stem cell mediated regenerative therapies, resulting in
an increasing need for a simpliﬁed means for easy, rapid and
economical acquisition of bone marrow.
Current operative marrow harvests generally require 200 tro-
car insertions into the donor’s ileac crest, with each puncture/
aspirate enabling withdrawal of a only a small volume of marrow.
O.R. based harvests require general anesthesia, multiple staff, sup-
portive RBC transfusions, and often an overnight hospital stay.
Peripheral blood stem cell harvests, while less invasive, often re-
quire several rounds of expensive GCSF administration and multi-
hours apheresis sessions. Each of these harvest methods incur
average costs over $15,000 per collection.
We have developed a novel harvest device, the “MarrowMiner”
for the rapid, minimally invasive extraction of bone marrow. This
method utilizes a single marrow entry site into the ileac bone,
through which a ﬂexible, powered, guidable catheter is able to
access the majority of the accessible marrow space. The Marrow-
Miner device will enable a single operator to rapidly harvest mar-
row in the outpatient setting, signiﬁcantly facilitating convenient,
on-demand stem cell collection, and should signiﬁcantly reduce
harvest costs and morbidity. Collected marrow could be utilized
immediately, or undergo manipulation for a variety of current and
potential future therapeutic indications.
The MarrowMiner device has been under preclinical develop-
ment in benchtop models, miniature swine and proof of concept
work in human cadavers. Data from device development will be
presented as a clinical grade version is being readied for human use.
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A PILOT TRIAL OF UNRELATED DONOR UMBILICAL CORD BLOOD
TRANSPLANATION (UCBT) AUGMENTED WITH CYTOKINE-PRIMED AL-
DEHYDE DEHYDROGENASE-BRIGHT (ALDHBR) CELLS
Kurtzberg, J.1, Balber, A.2, Mendizabal, A.3, Reese, M.1, Kaestner, A.1,
Gentry, T.2, Hickerson, D.2, Allen, C.3, Sledge, L.S.1, Deibert, E.2,
Allison, J.1, Baker, J.1, Haley, N.R.2 1Duke University Medical Center,
Durham, NC; 2Aldagen Incorporated, Durham, NC; 3The EMMES
Corporation, Rockville, MD.
The major obstacles to UCBT are delayed engraftment and
immune reconstitution due to the lower cell dose. Ex vivo expan-
sion of a portion of the CB graft to increase the number of cells
available for transplantation has been attempted with little to no
affect. We hypothesized that the expanded cells terminally differ-
entiated in culture exhauting their ability to further expand in vivo.
ALDHbr cells in cord blood are enriched for stem and progenitor
cells. These cells were cultured cells ex vivo with expansion of
mature and immature progenitors. We hypothesized that cells
would undergo further expansion if they were primed ex vivo for a
few days and then infused in vivo. We conducted a trial to test the
safety and feasibility of selecting, priming and infusing ALDHbr
cells isolated by high speed ﬂow cytometry from the 20% fraction
of banked CB stored in a dual compartment bags. ALDHbr cells
were isolated 6 days prior to transplant and primed in culture with
cytokines for 5 days. Release criteria included cell count, viability
and negative gram stain. Primed cells were infused 4 hours after
the conventional graft (80% fraction) on day 0. After written
informed consent, patients received sorted but unexpanded cells
(n4) or sorted and primed cells (n10). Safety was the primary
endpoint. Secondary endpoints included engraftment, immune re-
constitution and overall survival. Thus far 14 patients, (55% male,
82% Caucasian, median age 1.16 years) with pediatric malignant
(n6) or non-malignant (n8) diagnoses have been treated. CB
precryopreservation cell dose was 13.8910e7/kg with infused
dose 9.5310e7/kg. Four patients received51037cells/kg from
the 80% fraction. The yield of ALDHbr cells post sort was 50-
110K and remained stable during priming. No patient experienced
infusional toxicity. One patient died of persistant pulmonary hy-
pertension shortly after transplant. The other patients all survive
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